A Policy Debate on the Value & Cost of Treatment
Innovations in cancer therapy, particularly the development of targeted drugs and immunotherapies, hold remarkable potential to transform treatment of the disease. Increasingly, a new generation of cancer drugs is producing durable remissions and, potentially, cures. However, defining the value of cancer drugs is challenging. Numerous factors influence value, and the relative importance of each of these factors depends on the perspective of the stakeholders (patients, society, providers, payers, healthcare systems, manufacturers, researchers and academics). Though the needs of all stakeholders should be considered, patient benefit must be central when assessing value.
Participation fees with Early Bird Until 19 September
| Individual participation: 250€ + 24% VAT |
| 4 Company registrations (3+1 free): 750€ + 24% VAT |
| 8 Company registrations (6+2 free): 1500€ + 24% VAT |
Participation fees after 19 September
| Individual participation: 300€ + 24% VAT |
| 4 Company registrations (3+1 free): 900€ + 24% VAT |
| 8 Company registrations (6+2 free): 1800€ + 24% VAT |
Πότε;
Πέμπτη, 17 Οκτωβρίου 2019 9:00 πμΠού;
Divani Caravel HotelΛεωφόρος Βασιλέως Αλεξάνδρου 2
161 21 Αθήνα
Κεντρικός Τομέας Αθηνών,Ελλάδα
Προβολή μεγαλύτερου χάρτη